Progression Biobank of Achalasia and autoimmune gastritis

• Conditions: autoimmune metaplastic atrophic gastritis; gastrointestinal tumors; 10017969

• Registration Number: NL-OMON49853
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

Diagnosis of autoimmune gastritis or achalasia

Exclusion Criteria

History of surgery in the upper gastrointestinal tract, including the stomach
or esophagus.
Subjects with portal hypertension.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. Risk of malignant progression in AIG and achalasia.<br /><br>2. Infiltrating immune cells in biopsy from patients with AIG and achalasia.<br /><br>3. Autoantibodies in the serum from AIG and achalasia patients.<br /><br>4. The prevalence of HSV-1 and -2, human papillomavirus (HPV), human<br /><br>cytomegalovirus (HCMV), Epstein-Barr virus (EBV) and H. pylori infection in AIG<br /><br>and achalasia patients.<br /><br>5. HLA genotyping data in AIG and achalasia patients.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Investigate whether the diagnosis of achalasia can be performed by<br /><br>immunofluorescence imaging of serum on rat tissues (as is now routinely<br /><br>performed for AIG).<br /><br>2. Attempt to create an organoid biobank from freshly collected gastric and<br /><br>esophagus biopsies to set up a preclinical model to identify the specific<br /><br>autoantibody in achalasia and AIG.<br /><br>3. To evaluate the microbiota composition in the esophagus and gastric mucosa.</p><br>